Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics Inc. (KPTI) said the applicable parties further extended the Forbearance Period under the Forbearance Agreement and Limited Waiver to Indentures. The period will end at 11:59 p.m. Eastern time on November 1, 2026, absent earlier termination, replacing the prior end time of 11:59 p.m. Eastern time on October 22, 2026.
At Karyopharm Therapeutics Inc. (KPTI), Chief Accounting Officer Kristin Abate sold 4,788 common shares on October 16, 2026, at $0.3440 per share. Her reported direct holdings afterward were 18,616 shares. The broker-assisted sale satisfied withholding tax liability incurred upon vesting of restricted stock units and was made under a durable automatic sale instruction plan adopted May 27, 2021; the footnote states it was not discretionary.
Karyopharm Therapeutics Inc. (KPTI) disclosed that the applicable parties extended the end of the Forbearance Period under its Forbearance Agreement and Limited Waiver to Indentures. The period will end at 11:59 p.m. Eastern time on October 22, 2026, absent earlier termination, instead of October 15, 2026.
Karyopharm Therapeutics Inc. (KPTI) is the issuer in an amended ownership report listing Acorn Bioventures, L.P. with 429,101 shares (1.9%) and its general partner, Acorn Capital Advisors GP, LLC, with the same amount. Acorn Bioventures 2, L.P. and its general partner, Acorn Capital Advisors GP 2, LLC, are each reported with 592,567 shares (2.6%). Anders Hove, manager of both general partners, is reported with 1,021,668 shares (4.5%). The percentages use 22,681,460 shares outstanding as of June 30, 2026. The related entities’ reported beneficial-ownership positions overlap.
Karyopharm Therapeutics Inc. Chief Accounting Officer Kristin Abate sold 378 shares of common stock at $1.19 per share on October 1, 2026. After the sale, she directly held 23,404 shares. The broker-assisted sale satisfied withholding tax liability incurred upon vesting of restricted stock units and was described as not discretionary.
Karyopharm Therapeutics Inc. is named as the issuer in an amended Schedule 13G reporting beneficial ownership by Acorn Bioventures, L.P. (539,373 shares; 2.4%), Acorn Bioventures 2, L.P. (744,848 shares; 3.3%), and Anders Hove (1,284,221 shares; 5.7%). The two general partners are also listed at their respective fund’s share amount, and Hove is identified as manager of both. The percentages are based on 22,681,460 shares outstanding as of June 30, 2026.
Karyopharm Therapeutics Inc. is the issuer named in an amended Schedule 13G reporting beneficial ownership of its common stock by Acorn Bioventures, L.P., Acorn Bioventures 2, L.P. and Anders Hove. Acorn Bioventures, L.P. reported 539,373 shares (2.4%), and Acorn Bioventures 2, L.P. reported 744,848 shares (3.3%). Each partnership’s general partner reported the same corresponding amount.
Anders Hove, manager of both general partners, reported shared voting and dispositive power over 1,284,221 shares (5.7%). The reported ownership percentages are based on 22,681,460 shares outstanding as of June 30, 2026.
Karyopharm Therapeutics Inc. (KPTI) has issued a new series of senior convertible preferred stock to pay creditor fees tied to a recent forbearance agreement. On September 17, 2026, the company issued 20,000 shares of 0% Series A Convertible Perpetual Preferred Stock with a $1,000 initial liquidation preference per share, satisfying $20.0 million of fees owed under a fee agreement connected to its forbearance arrangements.
The preferred stock ranks senior to common stock for dividends and liquidation and is convertible into common stock at $1.62 per share, subject to caps and ownership limits until required Nasdaq stockholder approval is obtained. Before that approval, conversions are capped at an aggregate 4,520,000 common shares (less than 19.99% of pre-issuance common), with any excess generally settled in cash based on a 20‑trading‑day volume‑weighted average price, deferred until after the initial stockholder vote or March 15, 2027. The securities carry no regular dividends but unpaid cash amounts accrue at 2% per year, and holders gain significant protective and repurchase rights, including a one‑time put at $1,000 per share from September 17, 2029 and repurchase rights upon specified Fundamental Changes.
Karyopharm Therapeutics Inc. (KPTI) disclosed that it failed to pay a principal installment of approximately $15.8 million due September 10, 2026 under its Credit and Guaranty Agreement and previously missed cash interest payments on its 9.00% convertible notes, triggering or risking events of default and cross‑defaults across its credit, note and royalty agreements. The company entered into a Forbearance Agreement with its term‑loan lenders, all holders of its 9.00% Convertible Senior Notes due 2028 and 2029, and the revenue‑interest investors, under which these parties agreed to temporarily forbear from exercising remedies regarding these specified defaults through the earlier of October 15, 2026 or certain termination events, including liquidity falling below $10.0 million or adverse FDA action on its myelofibrosis sNDA. During this period, defaulted amounts under the credit facility and notes accrue an additional 2.00% per annum interest.
As consideration, Karyopharm agreed to pay $20.0 million in fees, to be satisfied by issuing 20,000 shares of 0% convertible perpetual preferred stock with a $1,000 liquidation preference and a conversion price of $1.62 per common share, subject to stockholder approval constraints that initially cap issuable common shares at 19.99% of voting power. The preferred stock carries a one‑time put right at $1,000 per share on or after the third anniversary and redemption rights upon a Fundamental Change. Karyopharm states that, based on its current plan and assuming the forbearance remains in effect through October 15, 2026, its liquidity is expected to fund operations only until that date, and that without additional funding or strategic transactions it will be unable to continue as a going concern and may need to pursue bankruptcy protection, asset sales or cease operations.
Karyopharm Therapeutics Inc. (KPTI) has a significant shareholder group led by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reporting beneficial ownership of 1,297,297 shares of common stock. This position represents 5.7% of Karyopharm’s outstanding common stock.
For each reporting person, there is no sole voting or dispositive power and 1,297,297 shares of shared voting and shared dispositive power. The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander, and the reporting persons state this should not be construed as an admission of beneficial ownership of those securities.